Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 1;8(8):8774-85.
eCollection 2015.

Effects of jnk inhibitor on inflammation and fibrosis in the ovary tissue of a rat model of polycystic ovary syndrome

Gulay Bulut  1 , Zehra Kurdoglu  2 , Yeliz Bozdemir Dönmez  3 , Mertihan Kurdoglu  4 , Remzi Erten  1
Affiliations

Effects of jnk inhibitor on inflammation and fibrosis in the ovary tissue of a rat model of polycystic ovary syndrome

Gulay Bulut et al. Int J Clin Exp Pathol. .

Abstract

Objective: In our study, we aimed to investigate the effects of Jun N-terminal kinase inhibitor (SP600125) on fibrosis and inflammation in rats with polycystic ovary syndrome (PCOS).

Method: 50 Wistar-albino rats were divided into five groups (n=10 each): control group, sham group, PCOS group, SP600125+ PCOS group and SP600125 group. In the estradiol valerate (EV)-treated group in which PCOS was injected with a single 4 mg/kg i.p. of EV in 0.2 ml sesame oil and the rats were sacrificed on day 60. The estradiol valerate (EV)-treated + SP600125-treated group was injected with a single 4 mg/kg i.p. of EV in 0.2 ml sesame oil. As of day 60, the treatment group was additionally given 15 mg/kg i.p. of SP600125 once daily for 4 consecutive days and the rats were sacrificed on day 65. Histopathological findings (ovarian morphology, edema, inflammatory cell infiltration, vascular congestion and hyperemia) and collagen type IV immunoexpression were assessed.

Results: The SP600125+ PCOS group showed a significant level of improvement in ovarian follicle morphology, edema, inflammatory infiltrate, vascular congestion and hyperemia as compared with the PCOS group. Furthermore, collagen type IV immunoexpression showed a significant reduction in staining intensity on the theca cell layer and ovary stroma as compared to the PCOS group.

Conclusion: This study demonstrates the therapeutic effect of SP600125 in the prevention of PCOS in an experimental model.

Keywords: Fibrosis; Jun N-terminal kinase inhibitor; inflammation; polycystic ovary syndrome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A. Section of an ovary from group 3 (H&E, ×40). B. Cystic degenerating follicles showing a thin granulosa layer and debris in follicular fluid (H&E, ×100). C. An atretic secondary follicle with granulosa cells showing signs of atresia and intact theca cells (H&E, ×200).
Figure 2
Figure 2
Histological examination of normal ovaries. Different developmental stages of follicles were detected in group 1 (A) (H&E, ×40), group 2 (B) (H&E, ×40), group 4 (C) (H&E, ×40), group 5 (D) (H&E, ×40).
Figure 3
Figure 3
Distribution of degree of edema of ovarian stroma.
Figure 4
Figure 4
Distribution of degree of vascular congestion and hyperemia.
Figure 5
Figure 5
Distribution of degree of inflammation.
Figure 6
Figure 6
Distribution of staining intensities among groups with collagen type IV staining in the ovarian stroma.
Figure 7
Figure 7
Distribution of staining intensities among groups with collagen type IV staining in the theca cell layer.
Figure 8
Figure 8
Expression of collagen type IV in rat ovaries. Group1 (A) (collagen type IV, ×100), group 2 (B) (collagen type IV, ×100) , group 5 (C) (collagen type IV, ×100), group 4 (D) (collagen type IV, ×100), group 3 (E, F) (collagen type IV, ×100, ×200).
See this image and copyright information in PMC

References

    1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006–4011. - PubMed
    1. Clément F, Monniaux D, Thalabard JC, Claude D. Contribution of a mathematical modelling approach to the understanding of the ovarian function. C R Biol. 2002;325:473–485. - PubMed
    1. Dumesic DA, Abbott DH. Implications of polycystic ovary syndrome on oocyte development. Semin Reprod Med. 2008;26:53–61. - PMC - PubMed
    1. Pache TD, Chadha S, Gooren LJ, Hop WC, Jaarsma KW, Dommerholt HB, Fauser BC. Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome? Histopathology. 1991;19:445–452. - PubMed
    1. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, Platanissiotis D, Kaklas N, Spina J, Georgiadou E, Hoffmann RG, Kissebah AH, Raptis S. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism. 1995;44:525–531. - PubMed

Publication types